Genmab A/S, one of Europe’s older biotech companies, is to acquire ProfoundBio Inc of the US for $1.8 billion giving it a pipeline of antibody-drug conjugates (ADC) and an opportunity to expand into treatments for gynecologic cancers and other solid tumours. The deal, which is expected to close during the first half, also represents a significant shift in the Danish company’s business model.
